Journal
JOURNAL OF VASCULAR RESEARCH
Volume 42, Issue 1, Pages 21-28Publisher
KARGER
DOI: 10.1159/000082873
Keywords
artery; restenosis; stents; signal transduction; Rho proteins; rapamycin
Categories
Ask authors/readers for more resources
In- stent restenosis is a novel pathobiologic process resulting from vascular smooth muscle cell ( VSMC) proliferation, migration and excessive matrix production. The present study was designed to assess the activity of RhoA, a major regulator of VSMC proliferation and migration, after stenting and to determine its role in the neointimal formation. Analysis of RhoA activity in an ex vivo organ culture model of human internal mammary arteries demonstrates that stenting induced a time-dependent increase in RhoA activity ( 4.9 +/- 0.4 vs. 1.2 +/- 0.2 in control at 28 days, n = 4, p < 0.0001) associated with a concomitant decrease in p27 expression. Treatment of stented arteries with the permeant RhoA inhibitor TAT- C3 ( 10 mu g/ ml) or Rho- kinase inhibitors ( Y- 27632, 10 mu mol/ l; fasudil, 10 mu mol/ l) inhibited both neointimal formation and decrease in p27 expression. Rapamycin ( 1 and 10 nmol/ l) also inhibited neointimal formation, and induced a loss of RhoA expression. The inhibitory effect of rapamycin on neointimal thickening is prevented by the dominant active form of RhoA. Our study shows that stent implantation induces maintained RhoA activation and demonstrates that the inhibitory action of rapamycin on RhoA expression plays a key role in its antirestenotic effect. Copyright (C) 2005 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available